The role of an aggrecan 32mer fragment in developing osteoarthritis
Project LeaderProfessor Amanda Fosang
The proteoglycan aggrecan is a key component of the cartilage matrix, responsible for enabling weight bearing, by providing compressive relilience. Aggrecan is degraded in early osteoarthritis (OA) and we have evidence to suggest that a fragment of aggrecan, the ‘32mer’, might initiate the inflammation that leads to cartilge pathology. We have a project funded by the USA Department of Defense to investigate whether a monoclonal antibody that neutralises 32mer activity will alleviate OA following acute joint injury.
- Ms Suzanne Golub, Research Assistant
- Ms Karena Last, Research Assistant
- Ms Jia-Xi Han, Research Assistant
- Ms Lynette Ong, PhD Student
- Dr Heather Stanton, Research Officer/Administrator
- Professor Hideaki Nagase, Kazuhiro Yamamoto & Dr Linda Troeberg, Kennedy Institute of Rheumatology, Oxford, UK
- Dr Anne-Marie Malfait & Dr Rachel Miller, Rush University, Chicago, USA
- Prof Alan Grodzinsky, Massachusetts Institute of Technology, Boston, USA
- Prof Virginia Kraus, Duke University, USA
- Prof Anders Aspberg, University of Copenhagen, Denmark
- Prof Frank Beier, University of Western Ontario, Canada
- Dr Paul Holden, Oregon Health & Science University, Oregon, USA
- Prof Danny Chan, University of Hong Kong, China
- A/Prof Philip Sutton, MCRI
- Prof John Bateman, MCRI
- A/Prof Shireen Lamande, MCRI
- Dr Marc Seal, Royal Children’s Hospital
- Prof David Jackson, University of Melbourne
- Prof Eleanor Mackie, University of Melbourne
- A/Prof Natalie Sims, St Vincent’s Institute, Melbourne
- Prof Chris Little, University of Sydney, NSW
- USA Department of Defense
- National Health & Medical Research Council
- Australian Research Council
This research project is available to PhD, Masters, Honours students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.
- Lees, S. Golub, SB., Last, K., Zeng, W., Jackson, DJ. &, Sutton, P. & Fosang, AJ. (2015) Bioactivity in an aggrecan 32-mer fragment is mediated via Toll-like receptor 2 Arthritis Rheumatol. 67, 1240-1249.